| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12002-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81046-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81062-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26547-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26470-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26688-50ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-26219-50ul | |||
![ELISA: Human DARC ELISA Kit (Colorimetric) [NBP3-27327] - Standard Curve Reference](http://images.novusbio.com/fullsize/nbp3-27327_human-darc-elisa-kit-colorimetric-114202410251012.png "ELISA: Human DARC ELISA Kit (Colorimetric) [NBP3-27327] - Standard Curve Reference")
![Flow Cytometry: CCR3 Antibody (5E8-G9-B4) - Chimeric [NBP2-81046] - Flow-cytometry using anti-CCR3 antibody (5E8-G9-B4) [NBP2-81046]. Human leukocytes were stained with an isotype control (NBP2-52638, panel A) or the rabbit-chimeric version of 5 E8-G9-B4 (NBP2-81046, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/CCR3-Antibody-5E8-G9-B4-Chimeric-Flow-Cytometry-NBP2-81046-img0001.jpg "Flow Cytometry: CCR3 Antibody (5E8-G9-B4) - Chimeric [NBP2-81046] - Flow-cytometry using anti-CCR3 antibody (5E8-G9-B4) [NBP2-81046]. Human leukocytes were stained with an isotype control (NBP2-52638, panel A) or the rabbit-chimeric version of 5 E8-G9-B4 (NBP2-81046, panel B) at a concentration of 1 ug/ml for 30 mins at RT. After washing, bound antibody was detected using a AF488 conjugated donkey anti-rabbit antibody and cells analysed on a FACSCanto flow-cytometer.")
![ELISA: GPRC5D Antibody (3D4) [NBP3-26547] - The Binding Activity of Human GPRC5D with GPRC5D Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human GPRC5D at 5 ug/mL can bind GPRC5D Antibody, the EC50 is 8.847-10.38 ng/mL.](http://images.novusbio.com/fullsize/nbp3-26547_human-gprc5d-mab-3d4-262202412272332.jpg "ELISA: GPRC5D Antibody (3D4) [NBP3-26547] - The Binding Activity of Human GPRC5D with GPRC5D Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human GPRC5D at 5 ug/mL can bind GPRC5D Antibody, the EC50 is 8.847-10.38 ng/mL.")
![ELISA: Complement Component C5aR1 Antibody (3A7) [NBP3-26470] - The Binding Activity of Human Complement Component C5aR1 with Complement Component C5aR1 Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human Complement Component C5aR1 at 10 ug/mL can bind Complement Component C5aR1 Antibody, the EC50 is 1.239-3.760 ng/mL.](http://images.novusbio.com/fullsize/nbp3-26470_human-complement-component-c5ar1-mab-3a7-262202412272333.jpg "ELISA: Complement Component C5aR1 Antibody (3A7) [NBP3-26470] - The Binding Activity of Human Complement Component C5aR1 with Complement Component C5aR1 Antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized Human Complement Component C5aR1 at 10 ug/mL can bind Complement Component C5aR1 Antibody, the EC50 is 1.239-3.760 ng/mL.")
![Flow Cytometry: CCR8 Antibody (2C10) [NBP3-26688] - Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (2ug/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.](http://images.novusbio.com/fullsize/nbp3-26688_human-ccr8-mab-2c10-282202414183623.jpg "Flow Cytometry: CCR8 Antibody (2C10) [NBP3-26688] - Untransfected CHO-K1 cells (green line) and transfected Human CCR8 CHO-K1 stable cells (red line) were stained with anti-CCR8 antibody (2ug/1*10^6 cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.")
![Flow Cytometry: Histamine H3R Antibody (27H8) [NBP3-26219] - Overlay Peak curve showing SH-SY5Y cells stained with Histamine H3R Antibody (27H8) (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% Triton X-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4C. Control antibody (green line) was rabbit IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed.](http://images.novusbio.com/fullsize/nbp3-26219_rabbit-histamine-h3r-mab-27h8-282202414183626.jpg "Flow Cytometry: Histamine H3R Antibody (27H8) [NBP3-26219] - Overlay Peak curve showing SH-SY5Y cells stained with Histamine H3R Antibody (27H8) (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% Triton X-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10^6 cells) for 45min at 4C. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG (H+L) at 1:200 dilution for 35min at 4C. Control antibody (green line) was rabbit IgG (1ug/1*10^6 cells) used under the same conditions. Acquisition of >10,000 events was performed.")